Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung CancerAlice T. Shaw, Pasi A. Jänne, Benjamin Besse et al.|New England Journal of Medicine|2013Cited by 3.4k
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialMartin Reck, Tony Mok, Makoto Nishio et al.|The Lancet Respiratory Medicine|2019Cited by 937
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancerLisa Derosa, Benjamin Besse, Bertrand Routy et al.|Nature Medicine|2022Cited by 637
Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung CancerV. Westeel, Élisabeth Quoix, Denis Moro‐Sibilot et al.|JNCI Journal of the National Cancer Institute|2005Cited by 142
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1Benjamin Besse, Enriqueta Felip, Rosario García Campelo et al.|Annals of Oncology|2023Cited by 69